Genome, expression module, recombinant strain and application thereof
By knocking out the sch9 gene in Saccharomyces cerevisiae, optimizing metabolic pathways and enzyme localization, the problem of insufficient lysergic acid biosynthesis production capacity was solved, and a significant increase in lysergic acid production and the improvement of anti-stress capacity of chassis cells was achieved.
Patent Information
- Application Number
- CN202411034494.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology is difficult to achieve high yield of lysergic acid biosynthesis in Saccharomyces cerevisiae. It is mainly because the chassis cells are not optimized, which makes the lysergic acid production capacity unable to meet industrial needs. The cell growth is poor under low-temperature fermentation conditions, which may cause strong cellular responses. Excited.
By knocking out the sch9 gene, strengthening the thiamine metabolism pathway and acetyl-CoA metabolic flow, and upregulating the gene encoding enzyme of the MVA pathway, optimizing the localization and function of the two rate-limiting enzymes of CloA and EasC, and improving the electrons between CloA and CPR Transmission efficiency, and communication between peroxisomes and mitochondria.
The yield of lysergic acid was significantly improved, from 3.43 mg/L to 59.69 mg/L, achieving efficient biosynthesis of lysergic acid in Saccharomyces cerevisiae, and optimizing the anti-stress ability and metabolic engineering strategies of chassis cells.
Smart Images

Figure BDA0004971510350000031 
Figure BDA0004971510350000032 
Figure BDA0004971510350000041
Abstract
Description
Technical Field
[0001] The present invention relates to the field of bioengineering, and in particular to genomes, expression modules, recombinant strains and applications thereof. Background Art
[0002] The use of cell factories to synthesize high value-added products is beneficial to environmental protection and sustainable bioeconomy. The development and optimization of microbial chassis cells are crucial to ensure the production efficiency of these factories. The model organism Saccharomyces cerevisiae has become a popular research object because of its clear genetic background, simple genetic manipulation and high safety. Sometimes, the synthesis of certain natural products in yeast requires catalysis by multi-step heterologous pathway enzymes, which may cause cell stress. In order to adapt to these long-path catalytic reactions, special fermentation conditions are sometimes required, which will further increase the stress burden of cells. In order to improve the stress resistance of cells, it is particularly important to regulate the global transcription of cells by screening some stress response factor targets, bring about some adaptive changes (such as readjusting the intracellular metabolic flux distribution or fine-tuning the intracellular environment), and enable the host to tolerate stress through these adaptive changes. At present, many studies have focused on improving cell tolerance by overexpressing stress response factors and analyzing their molecular mechanisms through transcriptomics. For example, overexpression of MSN4 improves yeast tolerance to betanin by triggering the transport mechanism. Overexpression of YCR102C can improve the efficiency of lignocellulose biorefining and improve resistance to 40°C and 3.6g / L acetic acid stress. More emphasis is placed on using anti-stress factors to improve the tolerance of cells to target compounds, while the adaptive changes of anti-stress factors in the global regulation of cells (such as readjusting the distribution of intracellular metabolic flux or fine-tuning the intracellular environment) are not fully utilized. Therefore, if these adaptive changes in the global regulation of cells can be utilized and some engineering strategies are further designed, it may lead to better compatibility of chassis cells with heterologous pathways.
[0003] Lysergic acid (LA) is an intermediate in the synthesis of many natural and semi-synthetic ergot alkaloids, such as ergonovine, neferol, and cabergoline, which are important active pharmaceutical molecules, and is in great demand in industry. At present, the biosynthesis of LA has been achieved in Saccharomyces cerevisiae and Aspergillus nidulans. The LA titer in yeast is 1.7 mg / L, and there is no report of LA titer in Aspergillus nidulans. In short, the production capacity of LA cannot meet the basic industrial commercial needs. The LA biosynthetic pathway consists of eight ergot alkaloid (EA) pathway enzymes (DmaW, EasF, EasE, EasC, EasD, EasA, EasG, and CloA). CloA belongs to the P450 enzyme, which is responsible for the continuous two-step oxidation of neferol to LA. At present, the traditional CloA optimization methods mainly focus on the screening of CloA isozymes, the adaptation of redox chaperone CPR isozymes to CloA, and the fusion expression of CloA-CPR proteins. All of these methods are effective strategies for optimizing P450 enzymes, but high yields of LA have not been achieved, probably because the chassis cells have never been optimized so far. Therefore, optimizing the potential yeast cell chassis is particularly important for achieving large-scale production of LA. In addition, it has been reported that EasC is a one-step rate-limiting enzyme responsible for the conversion of proergoline to proergoline. In Aspergillus nidulans, when the EasC copy number increases, proergoline still accumulates in large quantities. In yeast, lowering the fermentation temperature can improve the catalytic efficiency of the EasC rate-limiting step, and a yield of >500 mg / L of cycloergoline (downstream product) can be obtained. Low-temperature fermentation is more likely to obtain high yields of LA. However, in previous studies, it was found that the growth of field ergoline-producing bacteria was poor under low-temperature and high-density fermentation conditions. It is therefore speculated that low-temperature fermentation and the introduction of multi-step heterologous pathway enzymes may cause strong cellular stress, leading to growth discomfort. Therefore, it is urgent to optimize the yeast cell chassis to adapt to metabolic engineering strategies and increase the yield of LA. Summary of the invention
[0004] In view of this, the present invention provides a genome, an expression module, a recombinant strain and its application. The present invention intends to find the bottleneck point of lysergic acid synthesis from the perspective of optimizing the chassis, so as to increase the yield of lysergic acid by identifying and eliminating the bottleneck point.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides the use of knocking out sch9 gene in producing and / or preparing lysergic acid.
[0007] The present invention also provides the use of strengthening the thiamine metabolic pathway and / or acetyl-CoA metabolic flow in the production and / or preparation of lysergic acid.
[0008] The present invention also provides the use of an enzyme encoded by a gene that upregulates the MVA pathway in the production and / or preparation of lysergic acid.
[0009] The present invention also provides a genome, including: genome 1 and genome 2, and / or one or more of genomes 3 to 7;
[0010] The genome 1 comprises: a gene encoding a cytochrome P450 reductase derived from C. purpurea or a truncated gene thereof and / or a gene encoding a monooxygenase derived from C. purpurea;
[0011] The genome 2 includes: sch9 gene
[0012] The gene set 3 includes: stress factor genes;
[0013] The genome 4 includes: EasC gene;
[0014] The genome 5 includes: a signal peptide gene and / or a targeting signal peptide gene;
[0015] The genome 6 includes: a gene encoding a tethering protein;
[0016] The genome 7 includes: a connecting peptide gene.
[0017] In some embodiments of the present invention, in the above genome, the truncation site of the truncated gene encoding cytochrome P450 reductase is located at any one of L26, R31 or L36 at its n-terminus.
[0018] In some embodiments of the present invention, in the above genome, the truncation site of the truncated gene encoding cytochrome P450 reductase is located at L36 at its n-terminus.
[0019] In some embodiments of the present invention, in the above genome, the gene encoding the monooxygenase has:
[0020] (1) an amino acid sequence as shown in any of SEQ ID NO: 1 to SEQ ID NO: 3; or
[0021] (2) an amino acid sequence obtained by replacing, deleting or adding one or more amino groups of the amino acid sequence shown in (1), and having the same or similar function as the amino acid sequence shown in (1); or
[0022] (3) An amino acid sequence that is at least 80% identical to the amino acid sequence shown in (1) or (2).
[0023] In some embodiments of the present invention, in the above genome, the sequence of SEQ ID NO: 1 is:
[0024]
[0025] In some embodiments of the present invention, in the above genome, the sequence of SEQ ID NO: 2 is:
[0026]
[0027]
[0028] In some embodiments of the present invention, in the above genome, the sequence of SEQ ID NO:3 is:
[0029]
[0030] In some embodiments of the present invention, in the above genome, the stress factor genes include: one or more of: Hsp12 gene, OLE1 gene, SNF1 gene, TIP1 gene and MPP10 gene.
[0031] In some embodiments of the present invention, in the above genome, the stress factor gene is: SNF1 gene.
[0032] In some embodiments of the present invention, in the above genome, the signal peptide gene includes: KKYL gene and / or HDEL gene; the targeting signal peptide gene includes: SKL gene.
[0033] In some embodiments of the present invention, in the above genome, the signal peptide gene is: KKYL gene; the targeting signal peptide gene is: SKL gene.
[0034] In some embodiments of the present invention, in the above genome, the SKL gene replaces the ARL gene.
[0035] In some embodiments of the present invention, in the above genome, the SKL gene targets the EasC gene.
[0036] In some embodiments of the present invention, in the above genome, the gene encoding the tethering protein includes: Fzo1 gene or Pex34 gene.
[0037] In some embodiments of the present invention, in the above genome, the gene encoding the tethering protein is: Pex34 gene.
[0038] In some embodiments of the present invention, in the above genome, the connecting peptide gene includes: one or more of a helical connecting peptide gene, a rigid connecting peptide gene and a flexible connecting peptide gene.
[0039] The present invention also provides an expression module, comprising: the above genome.
[0040] In some embodiments of the present invention, the above expression module further includes: a promoter and a terminator.
[0041] In some embodiments of the present invention, in the above expression module, the promoter includes: an endogenous promoter of Saccharomyces cerevisiae; and the terminator includes an endogenous terminator of Saccharomyces cerevisiae.
[0042] In some embodiments of the present invention, in the above expression module, the promoter comprises: GAL110 .
[0043] In some embodiments of the present invention, in the above expression module, the terminator comprises: BA1t and / or T DH2t .
[0044] In some embodiments of the present invention, the above-mentioned expression modules include: one or more of expression modules 1 to expression modules 5;
[0045] The expression module 1 comprises: the gene encoding cytochrome P450 reductase and the gene encoding monooxygenase;
[0046] The expression module 2 includes: knocking out the sch9 gene;
[0047] The expression module 3 comprises: the gene encoding cytochrome P450 reductase, the gene encoding monooxygenase and the signal peptide gene;
[0048] The expression module 4 comprises: the EasC gene, the targeting signal peptide gene and the gene encoding the tethering protein;
[0049] The expression module 5 comprises: a truncated gene of the gene encoding cytochrome P450 reductase, the gene encoding monooxygenase, the connecting peptide gene and the signal peptide gene.
[0050] In some embodiments of the present invention, the above-mentioned expression modules include: one or more of expression modules 1 to expression modules 5;
[0051] The expression module 1 includes: YMRWΔ15up-trp-F BA1t -cloA-1-P GAL110 -CpCPR-T DH2t 、YMRWΔ15up-trp-F BA1t -cloA-2-P GAL110 -CpCPR-T DH2t or YMRWΔ15up-trp-F BA1t -cl oA-3-P GAL110 -CpCPR-T DH2t ;
[0052] The expression module 2 comprises: Δsch9;
[0053] The expression module 3 includes: BA1t -cloA-1-P GAL110 -CPR-T DH2t 、F BA1t -cloA-1_HDEL-P GAL110 -CPR_HDEL-T DH2t or F BA1t -cloA-1_KKYL-P GAL110 -CPR_KKYL-T DH2t ;
[0054] The expression module 4 includes: BA1t -easC-P GAL110 -T DH2t 、F BA1t -easC_SKL-P GAL110 -T D H2t 、F BA1t -Pex34-P GAL110 -T DH2t 、F BA1t -Fzo1-P GAL110 -T DH2t or F BA1t -easC_SKL-P GAL110 -Pex34-T DH2t ;
[0055] The expression module 5 comprises: BA1t -CPR-P GAL110 -T DH2t 、F BA1t -t26CPR-P GAL110 -T DH2t 、F BA1t -t31CPR-P GAL110 -T DH2t 、F BA1t -t36CPR-P GAL110 -T DH2t 、F BA1t -cloA-P GAL110 -t36CP RT DH2t 、F BA1t -P GAL110 -cloA-L1-t36CPR-T DH2t 、F BA1t -P GAL110 -cloA-L2-t36CPR-T DH2t 、FBA1t -P GAL110- cloA-L3-t36CPR-T DH2t or F BA1t -P GAL110 -cloA-L2-t36CPR_KKYL-T D H2t ;
[0056] The t26CPR is a gene truncated at L26 of the n-terminus of the cytochrome P450 reductase encoding gene; the t31CPR is a gene truncated at R31 of the n-terminus of the cytochrome P450 reductase encoding gene; the t36CPR is a gene truncated at L36 of the n-terminus of the cytochrome P450 reductase encoding gene;
[0057] The L1 is a helical connecting peptide gene; the L2 is a rigid connecting peptide gene; and the L3 is a flexible connecting peptide gene.
[0058] The present invention also provides a strain, in which the expression module 1 and the expression module 2 in the above expression modules are transformed and / or transfected into the chassis strain.
[0059] In some embodiments of the present invention, in the above-mentioned strains, the chassis strain includes: one or more of yeast, algae, enzyme bacteria and bacteria.
[0060] In some embodiments of the present invention, in the above strains, the yeast comprises any one of Saccharomyces cerevisiae, Saccharomyces lipolytica and Kluyveromyces.
[0061] In some embodiments of the present invention, in the above-mentioned strains, the enzyme-producing bacteria include: Streptomyces.
[0062] In some embodiments of the present invention, in the above-mentioned strains, the bacteria include: Escherichia coli or Bacillus subtilis.
[0063] In some embodiments of the present invention, in the above-mentioned strains, the chassis strain is: Saccharomyces cerevisiae.
[0064] In some embodiments of the present invention, among the above-mentioned strains, the chassis strain is: Saccharomyces cerevisiae CEN.PK2-1c.
[0065] The present invention also provides a recombinant strain, in which the expression module 3, the expression module 4 and the expression module 5 of the expression module are transformed and / or transfected.
[0066] The present invention also provides the use of the above genome, the above expression module, the above strain and / or the above recombinant strain in the preparation of lysergic acid.
[0067] The present invention also provides a method for synthesizing lysergic acid, which comprises culturing and fermenting the above-mentioned recombinant strain to obtain the lysergic acid.
[0068] The present invention provides the use of knocking out sch9 gene in producing and / or preparing lysergic acid.
[0069] Prior art realizes the de novo synthesis of lysergic acid in Saccharomyces cerevisiae by optimizing and screening the isozymes of the pathway enzymes in each step, but the metabolic flux is very low. This indicates that the bottleneck limiting the high yield of lysergic acid has not been found, and it may also be that the chassis cells and the heterologous pathway have poor compatibility. The present invention intends to find the bottleneck of lysergic acid synthesis from the perspective of optimizing the chassis. In order to increase the yield of lysergic acid by identifying and eliminating the bottleneck. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0071] Figure 1 The figure shows the construction and analysis of the biosynthesis pathway of lysergic acid; wherein: A shows that ergot alkaloids are oxidized to lysergic acid through two steps; B shows the effect of screening different cloA sequences on the yield of lysergic acid; C shows the results of LC-MS detection and analysis of fermentation samples;
[0072] Figure 2 The effects of stress factor screening on LA production are shown; A shows the effects of overexpression of different stress resistance factors on lysergic acid production and proline accumulation; B shows the effects of knocking out SCH9 on lysergic acid production and proline accumulation;
[0073] Figure 3 The effect of sch9 deficiency on lysergic acid is shown; A shows the volcano plot of differentially expressed genes between the Δsch9 strain and the control strain at 48 h; B shows the KEGG pathway DEGs enrichment analysis between the Δsch9 strain and the control strain at 48 h; C shows the transcriptional enrichment analysis of TCA cycle, MVA formation, peroxisomal fatty acid degradation and thiamine metabolism between the Δsch9 strain and the control strain;
[0074] Figure 4The figure shows that the reconfiguration of the spatial distance between CloA and CPR increases the production of lysergic acid; wherein: A shows the changes in the transcriptional levels of the transcriptional inhibitors of ribosome biogenesis and ergot alkaloid heterologous pathway enzymes stimulated by the strain after knocking out sch9; B shows a schematic diagram of the reconstruction of the spatial distance between CloA and CPR by different signal peptides on the endoplasmic reticulum, HDEL retains the protein in the endoplasmic reticulum cavity, and KKYL retains the protein in the endoplasmic reticulum but faces the cytoplasm; C shows the effect of different endoplasmic reticulum signal peptides on the production of lysergic acid in the Δsch9 strain and the control strain.
[0075] Figure 5 The figure shows the effect of enhanced peroxisome localization of EasC on lysergic acid; wherein: A shows the transcriptional changes of relevant endogenous genes in peroxisomes in the Δsch9 strain; B shows a schematic diagram of relocating EasC to peroxisomes and enhancing the interaction between peroxisomes and mitochondria; C shows the results of subcellular localization fluorescence analysis of peroxisomal marker Pex5-GFP and EasC-RFP-SKL fusion protein in the blank strain; D shows the effect of C-terminal peroxisomal signal peptide-modified EasC on lysergic acid production in the Δsch9 strain and the control strain; E shows the effect of enhanced interaction between peroxisomes and mitochondria on lysergic acid production in the Δsch9 strain and the control strain; F shows the effect of overexpression of effective targets for enhancing peroxisome-mitochondrial interaction and relocated EasC on lysergic acid production in the Δsch9 and control strains, respectively;
[0076] Figure 6 Schematic diagram of the reconstruction of the lysergic acid pathway in yeast; wherein: A is a schematic diagram of the truncation position of the CpCPRN end;
[0077] B shows the effect of different truncation positions at the CpCPRN end on the production of lysergic acid; C shows the effect of CloA and
[0078] The effects of different fusion proteins of CpCPR on lysergic acid production in Δsch9 and control strains; D shows the effect of the combination strategy on lysergic acid production. DETAILED DESCRIPTION
[0079] The invention discloses a genome, an expression module, a recombinant strain and applications thereof.
[0080] It should be understood that the expression "one or more of..." includes each of the items recited after the expression individually and in various different combinations of two or more of the recited items, unless otherwise understood from the context and usage. The expression "and / or" in combination with three or more recited items should be understood to have the same meaning, unless otherwise understood from the context.
[0081] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.
[0082] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.
[0083] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.
[0084] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.
[0085] The present invention optimizes chassis cells by screening anti-stress response factors, and analyzes the molecular mechanism by which overexpression of anti-stress response factors affects the global transcriptional regulation of chassis cells. Based on these molecular mechanisms and the problems existing in the lysergic acid biosynthesis pathway, metabolic strategies are customized to break through bottlenecks, thereby increasing the production of lysergic acid in brewer's yeast.
[0086] The basic scheme of the present invention comprises:
[0087] 1) First, cloA and CPR from C. purpurea were introduced into the ergot alkaloid production chassis to achieve heterologous synthesis of lysergic acid.
[0088] 2) In order to overcome the stress of low-temperature fermentation on cells, it was found that knocking out sch9 can effectively increase the production of lysergic acid during the screening of stress resistance factors. Transcription analysis showed that sch9 deletion significantly increased the level of cell translation and peroxisomal metabolism.
[0089] 3) Based on these two advantages of the Δsch9 chassis, a new engineering strategy was designed to optimize the two rate-limiting enzymes, CloA and EasC.
[0090] 3.1) By adding the signal peptide KKYL, the orientation of CloA and CPR on the endoplasmic reticulum is adjusted to the cytoplasmic side, thereby improving the efficiency of electron transfer between CloA and CPR.
[0091] 3.2) Transfer of EasC to peroxisomes can enhance the catalytic activity of EasC. Overexpression of Pex34 between peroxisomes and mitochondria enhances the communication between these two subcellular organelles, thereby facilitating the contact between the enzyme and its substrate.
[0092] 4) Finally, these customized engineering strategies were integrated into the Δsch9 chassis, gradually increasing the lysergic acid titer from 3.43 mg / L to 59.69 mg / L (17.4-fold), which is the highest lysergic acid titer and production reported in a heterologous host to date.
[0093] In conclusion, the advantages of our designed metabolic engineering strategy were maximized in the ΔSCH9 chassis, providing a general platform for optimizing the biosynthesis of ergot alkaloids.
[0094] Plasmids in the present invention:
[0095]
[0096]
[0097] The strains of the present invention are:
[0098]
[0099]
[0100] In Examples 1 to 5 of the present invention, all the raw materials and reagents used can be purchased from the market.
[0101] The present invention will be further described below in conjunction with embodiments:
[0102] Example 1 Construction of lysergic acid producing strain
[0103] The construction method of the recombinant Saccharomyces cerevisiae strain producing lysergic acid in this example is as follows:
[0104] 1. Obtaining a Saccharomyces cerevisiae strain for producing ergot alkaloids
[0105] Provided by Yuan Yingjin's research group, the strain number is SyBE_Sc06130019, corresponding to patent CN113308442A.
[0106] 2. Obtaining exogenous functional gene elements and modular integration tool plasmids
[0107] cloAs and CpCPR genes: synthesized by Jiutian Gene Technology (Tianjin) Co., Ltd.;
[0108] F BA1t , P GAL110 , T DH2t : Provided by Yuan Yingjin's research group, corresponding patent CN113308442A;
[0109] trp: amplified using the universal pRS414 plasmid as template;
[0110] 3. Construction of a Saccharomyces cerevisiae strain producing lysergic acid by yeast homologous recombination
[0111] According to YMRWΔ15up-trp-F BA1t -CloA-1 / CloA-2 / CloA-3-P GAL110 -CpCPR-T DH2t The sequence was designed, and the homology arm between each module was 50bp, which was introduced by primers; then the lithium acetate transformation method was used to co-transform into the ergot alkaloid production bacteria SyBE_Sc06130019, and the transformed yeast was coated on SC-TRP solid plates (synthetic yeast nitrogen source YNB 6.7g / L, glucose 20g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2g / L, 2% agar powder) for screening, and the transformants were selected for PCR verification sequencing, and the transformants with correct sequencing were streaked and pure cultured to obtain single colonies. The three correct yeast strains obtained were named: Sc244, Sc245 and Sc246.
[0112] 4. Fermentation of lysergic acid producing bacteria and LC-MS analysis
[0113] Test materials: strains Sc244, Sc245 and Sc246
[0114] Test method:
[0115] Seed medium (YPD): glucose 20 g / L, peptone 20 g / L, yeast extract powder 10 g / L;
[0116] Fermentation medium: 40g / L glucose, 20g / L peptone, 10g / L yeast extract powder.
[0117] A single colony of the above strain was inoculated into 5 mL of seed culture medium and cultured at 30°C and 250 rpm for 24 h. 600 =0.2 was transferred to 5 mL of fresh seed culture medium and cultured at 30°C and 250 rpm for 12 h. 600=0.1 was transferred to 50 mL of fermentation medium and fermented at 22°C and 250 rpm for 6 days to detect lysergic acid.
[0118] Lysergic acid extraction method: 1) Intracellular treatment method: Take 2mL of fermentation liquid from each fermentation bottle, centrifuge at 12000rpm for 2min to collect the bacteria, wash twice with sterile water and use for product extraction. The specific method is: resuspend the cells with 3M HCl, boil in a boiling water bath for 2min, then immediately ice bath for 3min, repeat four times; centrifuge the broken cells at 12000rpm and 4℃ for 5min to discard the supernatant, wash twice with sterile water, add 1mL of ethyl acetate, vortex for 5min, and extract repeatedly 3 times; centrifuge to enrich the ethyl acetate phase, and evaporate the ethyl acetate with a vacuum centrifugal concentrator, add 200μL of acetonitrile: water = 1:1, and filter with a 2μm organic filter membrane and detect with LC-MS. 2) Extracellular treatment method: Take 1mL of fermentation liquid, centrifuge at 12000rpm to collect the supernatant, filter with a 2.2μm water filter membrane and detect with LC-MS.
[0119] LC-MS detection method of lysergic acid: Q Exactive HF orbitrap mass spectrometer was used in conjunction with UltiMate3000rslnano (Thermo Fisher Scientific, USA) for positive ion mode LC-MS / MS analysis. The chromatographic column was a BEH amide column (2.1 mm×100 mm, Waters, USA). The mobile phase A was 100% acetonitrile plus 0.1% formic acid, and the mobile phase B was water plus 0.1% formic acid. Gradient elution was used for separation, from 5% (A) to 95% (A), with a flow rate of 0.3 mL / min for 20 min. The precursor used a mass resolution of 120,000. The specific ion source parameters were as follows: spray voltage, positive electrode was 3.5 kV; capillary temperature: 320°C; sheath gas flow rate (arb), 40; auxiliary gas flow rate (arb), 10; probe heater temperature, 350°C; mass range (m / z), 100-500.
[0120] LA is synthesized by two-step oxidation of argyrine by the P450 monooxygenase CloA. To achieve the biosynthesis of LA in the argyrine production chassis, we further introduced CloA. In the screening of different CloA isozymes, CloA from Claviceps purpurea has been shown to have the best catalytic efficiency. However, during the process of sorting out CloA in C. purpurea, we found that there were differences among the three sequences, with a contrast difference of 51.4%.
[0121] It has been reported that different CloA isozymes have different abilities to oxidize the substrate ergotamine in one step and two steps. Therefore, we selected three CloAs (named CloA-1, CloA-2, and CloA-3) as screening candidates for LA synthesis. Most microbial P450 catalytic systems require cytochrome P450 reductase (CPR). In addition, the compatibility between fungal P450 and heterologous CPR is much worse. In order to avoid the incompatibility between P450 CloA and heterologous CPR, the C. purpurea CPR was selected and the promoter P GAL110 Therefore, the three modules trp-cloA(x)-P GAL110 -CpCPR were integrated into the YMRWΔ15 locus of ergotamine-producing strains to generate strains Sc244-Sc246, which were then cultured in shake flasks containing YPD medium.
[0122] LC-MS analysis of intracellular and extracellular products showed that ergot alkaloids were mainly distributed in the extracellular region. Compared with the products of ergot alkaloid-producing strains, a new chromatographic peak ([M+H]+=255.15M / z) was detected in strains Sc244, Sc245 and Sc246, and a new chromatographic peak ([M+H]+=269.13M / z) was also detected in strain Sc244 ( Figure 1 C). The primary and secondary mass spectra of the product ([M+H]+=255.15M / z) were consistent with the mass spectrum of the ergotamine standard. The secondary mass spectrum of the product detected in this experiment ([M+H]+=269.13M / z) was consistent with the secondary mass spectrum of LA in the literature. Under the conditions where there was no significant difference in growth, no LA was detected in strains Sc245 and Sc246. In contrast, almost no intermediate product ergotamine was detected in strain Sc244, and almost all the substrate ergotamine was converted into the target product LA ( Figure 1 B), indicating that the CloA protein in this strain can continuously oxidize ergot alkaloids in two steps. Therefore, in subsequent studies, CloA-1 and strain Sc244 were used to optimize the synthesis of lysergic acid.
[0123] Table 1
[0124]
[0125] correspond Figure 1 Data of B.
[0126] Example 2 Global transcriptional analysis of the effect of sch9 deletion in the chassis on lysergic acid synthesis
[0127] The construction method of the anti-stress factor expression module in the present invention is as follows:
[0128] 1. Obtaining stress factor gene elements and modular integration tool plasmids
[0129] HSP12: SGD:S000001880;
[0130] OLE1: SGD:S000003023;
[0131] SNF1: SGD:S000002885;
[0132] TIP1: SGD:S000000271;
[0133] MPP10: SGD:S000003762;
[0134] Sch9: SGD:S000001248.
[0135] F BA1t , P GAL110 , T DH2t , Tool cutting plasmid CRISPR-Cas9: provided by Yuan Yingjin's research group, corresponding patent CN113308442A;
[0136] 2. Construction of yeast homologous recombination module
[0137] The universal shuttle expression plasmid pRS416 was used as the starting vector, and the endogenous promoter P GAL110 , terminator F BA1t , terminator T DH2t , press F BA1t -P GAL110 -T DH2t Sequentially insert into the universal shuttle expression plasmid pRS416 multiple cloning site NotI, where F BA1t -P GAL110 The BsaI restriction site is retained between GAL110 T DH2t The BsmBI restriction site is retained between the two, and the BsaI restriction site is used for the insertion of the stress factor gene sequence. The inserted BsaI restriction site sequence is: tttaggagaccggtctcccatt (as shown in SEQ ID NO:4), and the inserted BsmBI restriction site sequence is: aatgggagacgcgtctcctaaa (as shown in SEQ ID NO:5). The construction of the above expression vectors all adopts the in vitro seamless cloning and connection method, and the kit adopts the BM seamless cloning kit. The 5' end homology arm sequence of the stress factor gene is: gtcaaggagaaaaaactata (as shown in SEQ ID NO:6), and the 3' end homology arm sequence is: atttaactccttaagttact (as shown in SEQ ID NO:7), and the homology arm sequences are introduced by primer design.
[0138] The plasmid modules for expressing five stress factors were constructed as follows:
[0139] pRS416-F BA1t -Hsp12-P GAL110 -T DH2t ,
[0140] pRS416-F BA1t -OLE1-P GAL110 -T DH2t ,
[0141] pRS416-F BA1t -SNF1-P GAL110 -T DH2t ,
[0142] pRS416-F BA1t -TIP1-P GAL110 -T DH2t ,
[0143] pRS416-F BA1t -MPP10-P GAL110 -T DH2t ,
[0144] The sgRNA sequence used to knock out sch9 is: TTGGTCACTGATTATATGAG (as shown in SEQ ID NO: 8).
[0145] 3. Construction of a Saccharomyces cerevisiae strain producing lysergic acid by yeast homologous recombination
[0146] pRS416-F BA1t -P GAL110 -T DH2t , pRS416-F BA1t -Hsp12-P GAL110 -T DH2t , pRS416-F BA1t -OLE1-P GAL110 -T DH2t , pRS416-F BA1t -SNF1-P GAL110 -T DH2t , pRS416-F BA1t -TIP1-P GAL110 -T DH2t , pRS416-F BA1t -MPP10-P GAL110 -T DH2tThe six plasmids were transformed into Sc244, and the transformed yeast was coated on SC-URA solid plates (synthetic yeast nitrogen source YNB 6.7g / L, glucose 20g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2g / L, 2% agar powder) for screening. The obtained transformants were streaked for pure culture and single colonies were picked for PCR verification. The correct yeast verified by PCR was fermented. The 6 correct yeast strains obtained were named: Sc251, Sc295, Sc296, Sc297, Sc298, Sc302.
[0147] Construction of sch9 knockout strain: PCR amplification of the upstream homology arm up-sch9
[0148] (as shown in SEQ ID NO:9), downstream homology arm down-sch9
[0149] (As shown in SEQ ID NO: 10), 40bp homology arms were designed between the upstream and downstream homology arms by primers for overlapPCR, and the upstream and downstream homology arms were amplified by overlapPCR into a double-stranded DNA sequence for knocking out the donor of sch9. Then don nor and the CRISPR-cas9 tool plasmid were transformed into Sc244 by the lithium acetate method, and the transformed yeast was coated on SC-URA solid plate (synthetic yeast nitrogen source YNB 6.7g / L, glucose 20g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2g / L, 2% agar powder) for screening. The obtained transformants were streaked and pure cultured, and single colonies were picked for PCR rough verification, and the correct yeast verified by sequencing was fermented. The correct yeast strains obtained were named: Sc560.
[0150] 4. Fermentation and detection analysis of lysergic acid production strains are the same as above; the detection method of proline is the same as LA; Table 2 Transcription levels of key genes in TCA cycle, MVA pathway, peroxisomal fatty acid degradation pathway and thiamine metabolic pathway
[0151]
[0152] According to the survival habits of ergot fungi, low temperature is more conducive to the synthesis of ergot alkaloids. It has also been reported that the efficiency of converting N-Me-DMAT to chanoclavine-I can be improved by lowering the temperature in yeast. However, for the model organism host Saccharomyces cerevisiae, low temperature may cause stress by affecting cell activity (such as reducing translation and reducing membrane fluidity) and fermentation performance. In strain Sc251, we observed the accumulation of proline. The more proline accumulates, the stronger the anti-stress protection ability of yeast cells. Therefore, we selected five stress factors (Hsp12, OLE1, SNF1, TIP1 and MPP10) to overexpress in strain Sc244, trying to improve protein folding, cell membrane fluidity, ribosome biogenesis or translation under freezing stress. The results showed that strains Sc295 and Sc296 overexpressing Hsp12 and OLE1 had no significant effect on growth, nor did they promote the production of LA, and the proline accumulation of Sc296 was increased compared with the control strain Sc251. Among them, it has been reported that overexpression of Hsp12p can promote protein folding at low temperatures. OLE1, as a δ9 fatty acid desaturase, can increase the fluidity of the cell membrane at low temperatures. We speculate that the improvement in protein folding brought about by overexpression of Hsp12 at low temperatures may not be sufficient to induce a qualitative change in the flux of the LA allomer metabolic pathway controlled by the 9-step enzyme. The enhancement of cell membrane fluidity also cannot promote the efflux of LA. Compared with the control strain Sc251, strains Sc297, Sc298, and Sc302 overexpressing SNF1, TIP1, and MPP10, respectively, increased LA production, among which Sc297 had the most significant increase, increasing by 1.96 times. At the same time, the growth of the Sc297 strain increased slightly, and the accumulation of proline also decreased. MPP10 and TIP1 are both cold shock factors in yeast, which can increase the translation levels of ribosome complexes and mRNAs at low temperatures, respectively. Overexpression of SNF1 helps to improve the freezing resistance and fermentation ability of yeast cells.
[0153] Therefore, the increase in LA production may be due to the increase in the overall translation level of the cell or the improvement of the overall transcriptional stress of the cell. It is worth noting that SNF1 is an inhibitor of Sch9 and can adapt to the transcriptional stress response during glucose starvation. Therefore, we tried to eliminate Sch9 in the LA production chassis to replace the inhibitory effect of SNF1 on Sch9. Surprisingly, the LA production of the sch9 knockout strain Sc560 was 4.53 times that of the control strain Sc251 ( Figure 2 B). However, the proline content did not change significantly.
[0154] In order to analyze how sch9 deficiency affects the flux changes of the LA pathway, we selected samples at three time points for RNA-seq analysis. The three fermentation time points were 48 hours, when the strain was in the logarithmic growth phase and LA began to accumulate; 72 hours, when LA accumulation was in the middle; and 96 hours, when LA accumulation was in the late stage. Whole-genome transcriptome analysis showed that after sch9 deficiency for 48 hours, a total of 4339 genes were differentially expressed, of which 2124 genes were upregulated and 2215 genes were downregulated ( Figure 3 A). To further understand the functional classification of these DEGs and the related metabolic pathways they participate in, we performed a series of GO and KEGG pathway enrichment analyses. Among them, the significantly enriched pathways related to LA synthesis mainly involved "carbohydrate metabolism", such as the tricarboxylic acid cycle (TCA cycle) in peroxisomes (ko00020) and thiamine metabolism (ko00730), mevalonic acid (MVA) pathway and fatty acid degradation (ko00071) ( Figure 3 B).
[0155] In Saccharomyces cerevisiae, acetyl-CoA synthesizes DMAPP through the MVA pathway, and then DMAPP is catalyzed by eight EA enzymes to synthesize LA ( Figure 3C). Transcription results showed that during cell growth and the production and accumulation of LA, genes catalyzing the acetyl-CoA to MVA pathway (erg10, erg13) and eight EA heterologous genes responsible for catalyzing the conversion of dapp to LA were continuously upregulated (Table 2). At the same time, genes for fatty acid β-oxidation in peroxisomes (pox1, phs1, and pot1) were also continuously upregulated (Table 2). The upregulation of the fatty acid β-oxidation degradation pathway can increase the supply of acetyl-CoA, and under the pull of the upregulated MVA pathway and LA biosynthesis pathway, acetyl-CoA is more distributed to the metabolic flow of LA synthesis. It is worth noting that genes involved in the TCA cycle (idh1, sdh1, and cit1) were downregulated during cell growth and the production and accumulation of LA. During cell growth, genes encoding the catalytic synthesis of thiamine active substances ThdP (thi4, thi5, thi6, thi80) were upregulated. These genes were downregulated during the production and accumulation of LA (Table 2). ThdP is a cofactor that assists pyruvate dehydrogenase (PDH1) in promoting the conversion of pyruvate to acetyl-CoA. The TCA cycle flux is reduced. We assume that the competition for acetyl-CoA in the TCA cycle is weaker than in the MVA pathway. However, the thiamine metabolic pathway is upregulated, so we speculate that part of acetyl-CoA may enter the TCA cycle through feedback regulation of ThdP, thereby enhancing mitochondrial respiration, providing more energy for cell growth, and alleviating low temperature stress. In summary, knocking out sch9 can improve cell stress resistance by changing metabolic flux distribution, re-regulating intracellular homeostasis, and promoting lysergic acid synthesis, providing a promising strategy for optimizing matrix cells for the biosynthesis of ergot alkaloids.
[0156] Table 3
[0157] srtain LAmg / g OD600 LA-Standard Deviation OD600-Standard Deviation Proline mg / L Proline-SD Sc251 0.973436 12.8075 0.004431 0.070004 1.766728 0.00107167 Sc295 0.911269 12.8855 0.020791 0.33729 1.739771 0.00291637 Sc296 0.406575 10.442 0.112803 0.277186 3.922435 0.59562254 Sc297 2.871115 16.19 0.035022 0.120208 1.113258 0.00442059 Sc298 2.110705 11.3485 0.278941 0.08556 2.150601 0.03455791 Sc302 2.475874 14.6935 0.128665 0.098288 3.284641 0.26806727
[0158] correspond Figure 2 A's data.
[0159] Table 4
[0160] srtain LAmg / g OD600 LA-Standard Deviation OD600-Standard Deviation Proline mg / L Proline-SD Sc251 0.973436 12.8075 0.004431 0.070004 1.766728 0.001072 Sc560 1.603135 12.8155 0.302482 0.92136 1.695768 0.022484
[0161] correspond Figure 2 Data of B.
[0162] Example 3: Using the effect of chassis sch9 deletion on the increased level of cellular translation to design an engineering strategy to optimize the localization orientation of cloA and CPR on the endoplasmic reticulum
[0163] The method for constructing the expression module for optimizing the localization direction of cloA-1 and CPR on the endoplasmic reticulum in the present invention is as follows:
[0164] 1. Construction of expression modules for cloA-1 and CPR localization on the endoplasmic reticulum
[0165] The universal shuttle expression plasmid pRS416 was used as the starting vector, and the endogenous promoter P GAL110 , terminator F BA1t , terminator T DH2t , press F BA1t -P GAL110 -T DH2t Sequentially insert into the universal shuttle expression plasmid pRS416 multiple cloning site NotI, where F BA1t -P GAL110 The BsaI restriction site is retained between GAL110 -T DH2t The BsmBI restriction site is retained between them, the BsaI restriction site is used for the insertion of cloA-1, cloA-1_HDEL, cloA-1_KKYL gene sequences, and the BsmBI restriction site is used for the insertion of CPR, CPR_HDEL, and CPR_KKYL gene sequences. The inserted BsaI restriction site sequence is: tttaggagaccggtctcccatt (as shown in SEQ ID NO: 11), and the inserted BsmBI restriction site sequence is: aatgggagacgcgtctcctaaa (as shown in SEQ ID NO: 12). The construction of the above expression vectors all adopts the in vitro seamless cloning and connection method, and the kit adopts the BM seamless cloning kit. The homology arm sequence of the 5' end of the BsaI restriction site inserted gene is: gtcaaggagaaaaaactata (as shown in SEQ ID NO: 13), and the homology arm sequence of the 3' end is: atttaactccttaagttact (as shown in SEQ ID NO: 14), and the homology arm sequences are introduced by primer design. The homology arm sequence at the 5' end of the BsmBI restriction site insertion gene is: tttttgaaaattcaatataa (as shown in SEQ ID NO: 15), and the homology arm sequence at the 3' end is: gttaattcaaattaattgat (as shown in SEQ ID NO: 16), and the homology arm sequences are introduced by primer design.
[0166] The plasmids for constructing the three expression modules are as follows:
[0167] pRS416-F BA1t -cloA-1-P GAL110 -CPR-T DH2t ,
[0168] pRS416-F BA1t -cloA-1_HDEL-P GAL110 -CPR_HDEL-T DH2t ,
[0169] pRS416-F BA1t -cloA-1_KKYL-P GAL110 -CPR_KKYL-T DH2t ,
[0170] 2. Construction of a lysergic acid-producing Saccharomyces cerevisiae strain by homologous recombination
[0171] pRS416-F BA1t -cloA-1-P GAL110 -CPR-T DH2t ,
[0172] pRS416-F BA1t -cloA-1_HDEL-P GAL110 -CPR_HDEL-T DH2t ,
[0173] pRS416-F BA1t -cloA-1_KKYL-P GAL110 -CPR_KKYL-T DH2t ,
[0174] These three plasmids were transformed into Sc244 and Sc560, and the transformed yeast were coated on SC-URA solid plates (synthetic yeast nitrogen source YNB 6.7g / L, glucose 20g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2g / L, 2% agar powder) for screening. The obtained transformants were streaked for pure culture and single colonies were picked for PCR verification. The correct yeast verified by PCR was fermented.
[0175] 4. The fermentation and detection analysis of the lysergic acid producing strain is the same as in Example 1.
[0176] The enzyme CloA in the lysergic acid biosynthesis pathway belongs to the P450 enzyme. The main limitation of P450 biosynthesis of natural products is the low expression level of the enzyme and the low electron transfer efficiency of the redox ligand. During the fermentation process, Sch9 plays an important role in cellular translation, mainly by affecting the transcription inhibitors Hcm1, Hap4, Dot6 and Tod6 to stimulate ribosome biogenesis and promote protein synthesis. Transcriptomics results showed that Hap4, Dot6 and Tod6 were downregulated, while the enzymes encoding the LA pathway were upregulated, among which cloA was the most upregulated during the LA accumulation period ( Figure 4 A) These features validate Sch9 as a promising target for ergot alkaloid production in S. cerevisiae, where it can significantly increase cellular translation and promote the expression of heterologous pathway enzymes.
[0177] In the Δsch9 chassis with better translation ability, it may be more advantageous to amplify the advantages of the new strategy. Therefore, we tried to optimize the electron transfer efficiency of P450 and CPR in the chassis. Most p450s and CPRs are endoplasmic reticulum-associated proteins. The researchers used the membrane-associated progesterone receptor functional scaffold to reorganize the physical network of different P450S in the endoplasmic reticulum, thereby reducing the physical distance between different P450S in space and effectively increasing the production of quinone acid. There are two spatial distribution patterns of endoplasmic membrane chimeric proteins: one is the cytoplasm (assisted by the KKYL signal peptide) and the other is the endoplasmic reticulum (assisted by the HDEL signal peptide). Therefore, we proposed a method to artificially control the spatial distribution of CloA and CpCPR on the endoplasmic reticulum by adding additional signal peptides ( Figure 4 B). Then the CloA and CpCPR groups supplemented with KKYL and HDEL were divided into Δsch9 chassis and control chassis, respectively.
[0178] The results showed that the expression of CloA and CpCPR with different signal peptides in the control chassis had no significant effect on LA output. Compared with the control strain, the experimental strain expressing CloA and CpCPR and supplemented with the KKYL signal peptide showed a significant increase in LA production, with a 36.8% increase in production ( Figure 4 C). These results suggest that p450 and CPRs may indeed improve catalytic efficiency by regulating the orientation of the endoplasmic reticulum under favorable cellular translation conditions. It is noteworthy that after CloA and CpCPR with KKYL signal peptide were expressed in the Δsch9 chassis, the LA production was 2.98 times that of the control chassis ( Figure 4 C). In summary, these strategies were further exploited in the Δsch9 chassis, which provides a promising strategy for the synthesis of ergot alkaloids.
[0179] Table 5
[0180]
[0181] correspond Figure 4 C's data.
[0182] Example 4: Engineering strategies to eliminate EasC mislocalization by using the changes in peroxisomal metabolic flux caused by chassis sch9 deletion
[0183] The method for constructing the module for correcting EasC relocation and subcellular organelle interaction protein expression in the present invention is as follows:
[0184] 1. Construction of EasC relocalization and subcellular organelle interaction protein expression module
[0185] The universal shuttle expression plasmid pRS416 was used as the starting vector, and the endogenous promoter P GAL110, terminator F BA1t , terminator T DH2t , press F BA1t -P GAL110 -T DH2t Sequentially insert into the universal shuttle expression plasmid pRS416 multiple cloning site NotI, where F BA1t -P GAL110 The BsaI restriction site is retained between GAL110 -T DH2t The BsmBI restriction site is retained between them, the BsaI restriction site is used for the insertion of easC, easC_SKL, Pex34, and Fzo1 gene sequences, and the BsmBI restriction site is used for the insertion of the Pex34 gene sequence. The inserted BsaI restriction site sequence is: tttaggagaccggtctcccatt (as shown in SEQ ID NO: 17), and the inserted BsmBI restriction site sequence is: aatgggagacgcgtctcctaaa (as shown in SEQ ID NO: 18). The construction of the above expression vectors all adopts the in vitro seamless cloning and connection method, and the kit adopts the BM seamless cloning kit. The homology arm sequence of the 5' end of the BsaI restriction site inserted gene is: gtcaaggagaaaaaactata (as shown in SEQ ID NO: 19), and the homology arm sequence of the 3' end is: atttaactccttaagttact (as shown in SEQ ID NO: 20), and the homology arm sequences are introduced by primer design. The homology arm sequence at the 5' end of the BsmBI restriction site insertion gene is: tttttgaaaattcaatataa (as shown in SEQ ID NO: 21), and the homology arm sequence at the 3' end is: gttaattcaaattaattgat (as shown in SEQ ID NO: 22), and the homology arm sequences are introduced by primer design.
[0186] The plasmids for constructing the three expression modules are as follows:
[0187] pRS416-F BA1t -easC-P GAL110 -T DH2t ,
[0188] pRS416-F BA1t -easC_SKL-P GAL110 -T DH2t ,
[0189] pRS416-F BA1t -Pex34-P GAL110 -T DH2t ,
[0190] pRS416-FBA1t -Fzo1-P GAL110 -T DH2t ,
[0191] pRS416-F BA1t -easC_SKL-P GAL110 -Pex34-T DH2t .
[0192] 2. Construction of a lysergic acid-producing Saccharomyces cerevisiae strain by homologous recombination
[0193] pRS416-F BA1t -P GAL110 -T DH2t , pRS416-F BA1t -easC-P GAL110 -T DH2t , pRS416-F BA1t -easC_SKL-P GAL110 -T DH2t , pRS416-F BA1t -Pex34-P GAL110 -T DH2t , pRS416-F BA1t -Fzo1-P GAL110 -T DH2t , pRS416-F BA1t -easC_SKL-P GAL110 -Pex34-T DH2t The six plasmids were transformed into Sc244 and Sc560. The transformed yeast were coated on SC-URA solid plates (synthetic yeast nitrogen source YNB 6.7 g / L, glucose 20 g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2 g / L, 2% agar powder) for screening. The obtained transformants were streaked for pure culture and single colonies were picked for PCR verification. The correct yeast verified by PCR was fermented.
[0194] 3. The fermentation and detection analysis of the lysergic acid producing strain are the same as those in Example 1.
[0195] EasC has been shown to be the rate-limiting enzyme in the biosynthesis of naked ergot alkaloids, and studies have also confirmed that O2 is an oxidant that promotes the enzyme activity of EasC in the redox reaction catalyzed by EasC. We speculate that EasC may play a better catalytic role in a good peroxisomal environment. In previous studies, we found that EasC could not localize peroxisomes in yeast hosts through its own peroxisomal signal peptide ARL. ARL belongs to the peroxisome targeting signal peptide PTS1. In order to correct the correct localization of EasC to peroxisomes in yeast, we chose to replace ARL with SKL of the same type, and recorded the replaced EasC as EasC (SKL). In order to verify that SKL can enable EasC to migrate to the peroxisome, we chose PEX5 as a peroxisome marker protein fused with GFP, and EasC (SKL) was fused with RFP. Confocal laser scanning observed the overlap of red and green fluorescence in the cell ( Figure 5 C), showing that EasC is relocalized to peroxisomes after the signal peptide SKL is replaced.
[0196] Transcriptomics results showed that the peroxisomes of Δsch9 cells were significantly different. Coincidentally, during LA synthesis, faa2, faa4, pox1, phs1, and pot1 in the peroxisomal fatty acid β-oxidation pathway were significantly upregulated. The β-oxidation pathway metabolizes and accumulates H2O2, and excessive H2O2 can cause oxidative stress and cell damage. Catalase (CTA1) was significantly upregulated in the late stage of LA accumulation, enabling catalase (CTA1) to decompose the accumulated H2O2 metabolized by the β-oxidation pathway into O2 and H2O, achieving the purpose of detoxification ( Figure 5 A). Therefore, the O2 content in the peroxisomes of Δsch9 cells is higher. This can provide more oxidants for the EasC-catalyzed reaction. EasC and EasC(SKL) were then introduced into the control chassis and the Δsch9 chassis, respectively. The results showed that overexpression of EasC or EasC(SKL) in both the control chassis and the Δsch9 chassis significantly increased LA production. In addition, in the Δsch9 chassis, the amount of LA produced by overexpressing EasC(SKL) was 2.2 times the amount of LA produced by overexpressing EasC(SKL) in the control chassis ( Figure 5 C) This further demonstrates that Δsch9 cells indeed provide an efficient peroxisomal environment for EasC expression.
[0197] In previous studies, it has been confirmed that EasD and EasG are located in mitochondria, and EasA is located in peroxisomes ( Figure 5B). We proposed an idea to try to shorten the distance between peroxisomes and mitochondria by strengthening the interacting proteins between the two organelles. This would not only solve the problem of long-distance transport between enzymes and substrates, but also transport acetyl-CoA, the final product of the fatty acid β-oxidation pathway in peroxisomes, to mitochondria through the Krebs cycle, thereby increasing mitochondrial respiration. Fzo1 and Pex34 are two tethering proteins between peroxisomes and mitochondria. Fzo1 and Pex34 were overexpressed in the control chassis and the Δsch9 chassis, respectively. The results showed that overexpression of Fzo1 and Pex34 increased LA production to varying degrees, with Pex34 having the best effect. After overexpressing PEX34 in the Δsch9 chassis, the output of LA was 1.97 times that of the control chassis expression level ( Figure 5 E). We then overexpressed EasC (SKL) and PEX34 in the control chassis and Δsch9 chassis at the same time. Although the production of LA did not achieve the expected coordination effect, it was also higher than the production of the overexpressed target genes ( Figure 5 F). The application of this strategy also provides a new research direction for synthesizing other natural products under the condition of regulating the chain connection between subcellular organelles without changing the subcellular compartments of pathway enzymes. At the same time, it further highlights the advantages of the Δsch9 chassis.
[0198] Table 6
[0199]
[0200] correspond Figure 5 D's data.
[0201] Table 7
[0202]
[0203] correspond Figure 5 Data of E.
[0204] Table 8
[0205]
[0206] correspond Figure 5 Data of F.
[0207] Example 5: Reconstructing the synthetic pathway of lysergic acid by combining beneficial strategies in the sch9-deficient chassis
[0208] The method for constructing the expression module of CPR truncation and cloA and CPR fusion protein in the present invention is as follows:
[0209] 1. Construction of expression modules for CPR truncation and cloA and CPR fusion proteins
[0210] The universal shuttle expression plasmid pRS416 was used as the starting vector, and the endogenous promoter P GA L110 , terminator F BA1t , terminator T DH2t , press F BA1t -P GAL110 -T DH2t Sequentially insert into the universal shuttle expression plasmid pRS416 multiple cloning site NotI, where F BA1t -P GAL110 The BsaI restriction site is retained between GAL110 -T DH2t The BsmBI restriction site is retained, the BsaI restriction site is used for the insertion of CPR, t26CPR, t31CPR, t36CPR, cloA-1 gene sequences, and the BsmBI restriction site is used for the insertion of t36CPR, cloA-1-L1-t36CPR, cloA-1-L2-t36CPR, cloA-1-L3-t36CPR, cloA-1-L2-t36CPR_KK YL gene sequences. The inserted BsaI restriction site sequence is: tttaggagaccggtctcccatt (as shown in SEQ ID NO: 23), and the inserted BsmBI restriction site sequence is: aatgggagacgcgtctcctaaa (as shown in SEQ ID NO: 24). The construction of the above expression vectors all adopts the in vitro seamless cloning and connection method, and the kit adopts the BM seamless cloning kit. The homology arm sequence at the 5' end of the BsaI restriction site insertion gene is: gtcaaggagaaaaaactata (as shown in SEQ ID NO: 25), and the homology arm sequence at the 3' end is: attt aactccttaagttact (as shown in SEQ ID NO: 26), and the homology arm sequences are introduced by primer design. The homology arm sequence at the 5' end of the BsmBI restriction site insertion gene is: tttttgaaaattcaatataa (as shown in SEQ ID NO: 27), and the homology arm sequence at the 3' end is: gttaattcaaattaattgat (as shown in SEQ ID NO: 28), and the homology arm sequences are introduced by primer design.
[0211] The plasmids for constructing the three expression modules are as follows:
[0212] pRS416-F BA1t -CPR-P GAL110 -T DH2t ,
[0213] pRS416-F BA1t -t26CPR-P GAL110 -TDH2t ,
[0214] pRS416-F BA1t -t31CPR-P GAL110 -T DH2t ,
[0215] pRS416-F BA1t -t36CPR-P GAL110 -T DH2t ,
[0216] pRS416-F BA1t -cloA-1-P GAL110 -t36CPR-T DH2t ,
[0217] pRS416-F BA1t -P GAL110 -cloA-1-L1-t36CPR-T DH2t ,
[0218] pRS416-F BA1t -P GAL110 -cloA-1-L2-t36CPR-T DH2t ,
[0219] pRS416-F BA1t -P GAL1100 -cloA-1-L3-t36CPR-T DH2t ,
[0220] pRS416-F BA1t -P GAL110 -cloA-1-L2-t36CPR_KKYL-T DH2t .
[0221] 2. Construction of a lysergic acid-producing Saccharomyces cerevisiae strain by homologous recombination
[0222] pRS416-F BA1t -P GAL110 -T DH2t , pRS416-F BA1t -CPR-P GAL110 -T DH2t , pRS416-F BA1t -t26CPR-P GAL110 -T DH2t , pRS416-F BA1t -t31CPR-P GAL110 -T DH2t , pRS416-F BA1t -t36CPR-PGAL110 -T DH2t , these five plasmids were transformed into Sc244, and the transformed yeast was coated on SC-URA solid plates (synthetic yeast nitrogen source YNB 6.7g / L, glucose 20g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2g / L, 2% agar powder) for screening. The obtained transformants were streaked for pure culture and single colonies were picked for PCR verification. The yeast verified by PCR was fermented. The lithium acetate method was also used to separate pRS416-F BA1t -cloA-1-P GAL110 -t36CPR-T DH2t , pR S416-F BA1t -P GAL110 -cloA-1-L1-t36CPR-T DH2t , pRS416-F BA1t -P GAL110 -cloA-1-L2-t36CPR-T DH2t , pRS416-F BA1t -P GAL110 -cloA-1-L3-t36CPR-T DH2t The four plasmids were transformed into Sc244 and Sc560. The transformed yeast were coated on SC-URA solid plates (synthetic yeast nitrogen source YNB 6.7 g / L, glucose 20 g / L, mixed amino acid powder lacking tryptophan, leucine, histidine and uracil 2 g / L, 2% agar powder) for screening. The obtained transformants were streaked for pure culture and single colonies were picked for PCR verification. The correct yeast verified by PCR was ready for fermentation.
[0223] 3. Construction of Sc592 with the highest lysergic acid production: In the knockout sch9 chassis, the best fusion protein P was firstly transformed into GAL1 -cloA-1-L2-t36CPR-T DH2t The module was integrated into the genome ΔYPR Cτ3 (sgRNA sequence: tattccatggcctcttagtt (as shown in SEQ ID NO: 29)), and then the module F was selected by the G418 antibiotic marker. BA1t -easC_SKL-P GAL110 -Pex34-T DH2t Integrated into the genomic TY1 site, and finally introduced into the plasmid pRS416-F BA1t -P GAL110 -cloA-1-L2-t36CPR_KKYL-T DH2t The Sc592 strain was obtained.
[0224] 4. Lysergic acid detection and analysis are the same as in Example 1.
[0225] To construct a high-yield LA recombinant Saccharomyces cerevisiae, we assembled all the beneficial strategies in the Δsch9 chassis. In the Δsch9 chassis, CloA and CpCPR redefined their spatial distribution in the ER by adding a C-terminal KKYL signal peptide, which significantly increased the production of LA. We suspect that if CloA and CpCPR are not oriented toward the cytoplasmic side at the same time on the ER, they may create a spatial barrier. In addition, the fusion of 450 protein with its reductase domain has also been shown to be a way to improve the efficiency of electron transfer. The fusion protein shortens the physical distance between the two enzymes in the plane, thereby improving the biosynthesis of the target compound. However, when CloA and CpCPR are fused, their positioning may be consistent with one of the CloA and CpCPR proteins, or inconsistent with both proteins. Therefore, we speculate that adding a KKYL signal peptide to the C-terminus of the CloA and CpCPR fusion protein can shift its orientation on the ER to the cytoplasmic side, which can not only improve the efficiency of electron transfer, but also prevent the substrate from crossing the endoplasmic membrane to reach the enzyme.
[0226] First, in order to construct CloA and CpCPR fusion proteins, we tried to optimize the N-terminal domain of CpR with different truncation degrees and searched for the best truncation position based on the putative disordered region (M9-M31) of CpCPR predicted by PSIPRED Workbench (http: / / bioinf.cs.ucl.ac.uk / psipred / ). Figure 6 As shown in A, CpCPR was truncated at three different positions along the gradient within its n-terminus L26, R31 and L36, generating proteins t26CpCPR, t31CpCPR and t36CpCPR, respectively. The three n-truncated CpCPR proteins and the original CpCPR protein were introduced into strain Sc244, and their corresponding LA output was measured. The results showed that the LA production of strain Sc290 expressing t36CpCPR increased by 47.8% and 75.3% (compared with the control strain Sc287 and the original control strain Sc251, respectively). Figure 6 B). It was further demonstrated that truncating the n-terminus of CpCPR could obtain higher yields than increasing the copy number of the same CpCPR. Therefore, we selected t36CpCPR as a candidate gene for constructing CloA fusion protein.
[0227] The type of peptide linker in enzyme fusion affects the production of target compounds. Therefore, we selected three different types of peptide linkers: helical linker (L1-(EAAAK)2), rigid linker (L2-(PT)4P) and flexible linker (L3-GGGGS). Then, the fusion proteins were introduced into the Δsch9 chassis and the control chassis, respectively. The results showed that compared with the control strain, the CloA-L2-t36CpCPR fusion protein significantly increased the LA production of the two chassis, respectively, but there was no statistically significant difference in LA production between the two chassis ( Figure 6 C). We hypothesized that the CloA-L2-t36CpCPR fusion protein might not be restricted by cellular translation.
[0228] Subsequently, in order to stabilize the inheritance of the gene and promote the accumulation of LA, the module P GAL110 -cloA-1-L2-t36CpCPR and moduleeasC(SKL)-P GAL110 -pex34 was integrated into the genome to obtain strain Sc590. Finally, the module CloA-1-L2-t36CpCPR with a KKYL signal peptide added to the C-terminus and the module without a KKYL signal peptide were introduced into strain Sc590. The results showed that the LA production of Sc592 increased by 32.6% and 47.4% compared with Sc590 and Sc591, respectively ( Figure 6 D). The spatial distribution of the fusion protein CloA-1-L2-t36CpCPR on the endoplasmic reticulum was redefined by the KKYL signal peptide, which may further eliminate the spatial barrier between the enzyme and the substrate and improve the efficiency of electron transfer. In short, through the optimization of the above strategies, the yield of LA gradually increased from 3.43 mg / L to 59.69 mg / L. This is the highest yield in Saccharomyces cerevisiae.
[0229] Table 9
[0230] srtain LAmg / g Standard Deviation Sc290 1.699912 0.07875 Sc289 1.486573 0.011941 Sc288 1.492539 0.149164 Sc287 1.151596 0.069435 Sc251 0.973436 0.004431
[0231] correspond Figure 6 Data of B.
[0232] Table 10
[0233]
[0234] correspond Figure 6 C's data.
[0235] Table 11
[0236] strain LAmg / L Standard Deviation Sc251 3.434755 0.055524 Sc560 9.768281 0.486118 Sc577 27.46796 0.458448 Sc590 45.01225 2.448749 Sc591 40.49583 1.398038 Sc592 59.69498 0.884175
[0237] correspond Figure 6 D's data.
[0238] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of knocking out the sch9 gene in the production and / or preparation of lysergic acid.
2. A genome, characterized in that include: One or more of genome 1 and genome 2, and / or genome 3 to genome 7; The genome 1 comprises: a gene encoding a cytochrome P450 reductase derived from C. purpurea or a truncated gene thereof and / or a gene encoding a monooxygenase derived from C. purpurea; The genome 2 includes: sch9 gene The gene set 3 includes: stress factor genes; The genome 4 includes: EasC gene; The genome 5 includes: a signal peptide gene and / or a targeting signal peptide gene; The genome 6 includes: a gene encoding a tethering protein; The genome 7 includes: a connecting peptide gene.
3. The genome according to claim 2, characterized in that The truncation site of the truncated gene encoding cytochrome P450 reductase is located at any one of L26, R31 or L36 at its N-terminus.
4. The genome according to claim 2 or 3, characterized in that The gene encoding the monooxygenase has: (1) an amino acid sequence as shown in any of SEQ ID NO: 1 to SEQ ID NO: 3; or (2) an amino acid sequence obtained by replacing, deleting or adding one or more amino groups of the amino acid sequence shown in (1), and having the same or similar function as the amino acid sequence shown in (1); or (3) An amino acid sequence that is at least 80% identical to the amino acid sequence shown in (1) or (2).
5. The genome according to any one of claims 2 to 4, characterized in that The stress factor genes include: one or more of Hsp12 gene, OLE1 gene, SNF1 gene, TIP1 gene and MPP10 gene.
6. The genome according to any one of claims 2 to 5, characterized in that The signal peptide gene includes: KKYL gene and / or HDEL gene; the targeting signal peptide gene includes: SKL gene.
7. The genome according to any one of claims 2 to 6, characterized in that The gene encoding the tethering protein includes: Fzo1 gene or Pex34 gene.
8. The genome according to any one of claims 2 to 7, characterized in that The connecting peptide gene includes one or more of a helical connecting peptide gene, a rigid connecting peptide gene and a flexible connecting peptide gene.
9. An expression module, characterized in that include: The genome according to any one of claims 2 to 8.
10. The expression module according to claim 9, characterized in that include: One or more of expression modules 1 to 5; The expression module 1 comprises: the gene encoding cytochrome P450 reductase and the gene encoding monooxygenase; The expression module 2 includes: knocking out the sch9 gene; The expression module 3 comprises: the gene encoding cytochrome P450 reductase, the gene encoding monooxygenase and the signal peptide gene; The expression module 4 comprises: the EasC gene, the targeting signal peptide gene and the gene encoding the tethering protein; The expression module 5 comprises: a truncated gene of the gene encoding cytochrome P450 reductase, the gene encoding monooxygenase, the connecting peptide gene and the signal peptide gene.
11. A strain characterized in that The expression module 1 and the expression module 2 in the expression module according to claim 9 or 10 are transformed and / or transfected into a chassis strain.
12. A recombinant strain, characterized in that The expression module 3, the expression module 4 and the expression module 5 of the expression module according to claim 9 or 10 are transformed and / or transfected into the strain according to claim 11.
13. Use of the genome according to any one of claims 2 to 8, the expression module according to claim 9 or 10, the strain according to claim 11 and / or the recombinant strain according to claim 12 in the preparation of lysergic acid.
14. A method for synthesizing lysergic acid, characterized in that: The recombinant strain according to claim 12 is cultured and fermented to obtain the lysergic acid.
Citation Information
Cited By
CYP76AD1-alpha branched protein and application thereof in betanin biosynthesis
CN116042548A
